Chimeric Therapeutics Ltd
Company Profile
Business description
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
Contact
62 Lygon Street
Level 3, Carlton
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,059.10 | 29.60 | 0.33% |
| CAC 40 | 7,827.45 | 44.57 | -0.57% |
| DAX 40 | 23,666.81 | 55.48 | 0.23% |
| Dow JONES (US) | 46,121.28 | 171.50 | -0.37% |
| FTSE 100 | 9,250.43 | 27.11 | 0.29% |
| HKSE | 26,479.19 | 39.46 | -0.15% |
| NASDAQ | 22,497.86 | 75.62 | -0.33% |
| Nikkei 225 | 45,724.21 | 93.90 | 0.21% |
| NZX 50 Index | 13,153.79 | 27.52 | -0.21% |
| S&P 500 | 6,637.97 | 18.95 | -0.28% |
| S&P/ASX 200 | 8,769.00 | 31.10 | 0.36% |
| SSE Composite Index | 3,845.40 | 8.24 | -0.21% |